In-depth view of key statistics and finances for EDITAS MEDICINE, INC. (EDIT) on MSN Money. Editas Medicine's share price could stay at $48.00 by May 10, 2022. The high price target for EDIT is $86.00 and the low price target for EDIT is $14.00. In the short term (2weeks), EDIT's stock price should outperform the market by 1.60%.During that period the price should oscillate between -10.24% and +13.07%.. ET to provide a corporate update and results for the second quarter of 2021. Thursday, June 18, 2020. 08:21 AM ET. Since then, EDIT stock surged by 270.72%, with an average of 54.14% per year. Editas Medicine Inc. (EDIT) saw an uptrend of 2.85% in the recent trading with $43.60 being its most recent. Editas Medicine Inc has risen higher in 3 of those 5 years over the subsequent 52 week period, corresponding to a … CRISPR Stock Forecast: Genome editing has passed from science fiction to science fact. Overall. EDIT lost -$1.72 per share the over the last 12 months. IV can help traders determine if options are fairly valued, undervalued, or overvalued. Editas Medicine, Inc. is estimated to report earnings on 08/05/2021. Dive deeper with interactive charts and top stories of EDITAS MEDICINE, INC.. ... Editas Medicine, Inc. (NASDAQ:EDIT) Forecast to … , 1D Long. Editas Medicine price target raised to $65 from $46 at Raymond James, stock rating outperform MarketWatch. Editas Medicine Inc (EDIT:NSQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. What this means: InvestorsObserver gives Editas Medicine Inc (EDIT) an overall rank of 27, which is below average. EDITAS MEDICINE INC stock price forecast for further price development down to -5.99% (time horizon: 1 day) and price target of 39.85 USD. The average price target represents a 32.08% upside from the last price of $35.86. The average Editas Medicine stock forecast 2022 represents a 6.12% increase from the last price of $46.0699996948242. With a 5-year investment, the revenue is expected to be around +133.62%. ... Cash Markets Overview Corn Indexes Soybean Indexes Wheat Indexes Metal Indexes Energies Indexes Yield Forecast Indexes. Editas Medicine Inc (EDIT) stock has risen 18.87% while the S&P 500 is down -0.42% as of 1:11 PM on Wednesday, Dec 9. Their average twelve-month price target is $54.50, predicting that the stock has a possible downside of 3.52%. Based on our forecasts, a long-term increase is expected, the "EDIT" stock price prognosis for 2026-07-06 is 102.231 USD. It's been a pretty great week for Editas Medicine, Inc. (NASDAQ:EDIT) shareholders, with its shares surging 11% to US$24.71 in the week since its latest quarterly results.Revenues of US$5.7m fell short of estimates by 15%, but statutory losses were tightly controlled, with the per-share loss of US$0.69 being 12% smaller than consensus predictions. The stock's last reported lowest price was 44.63. https://www.fool.com/investing/2021/01/26/is-editas-medicine-a-buy The Editas Medicine, Inc. (NASDAQ:EDIT) share price has had a bad week, falling 13%.On the bright side the share price is up over the last half decade. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. Furthermore, Editas Medicine Inc. (EDIT)’s beta value is 1.95, and its average true range (ATR) is 3.58. The analysts covering Editas Medicine, Inc. (NASDAQ:EDIT) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for next year.There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic. EDIT Stock Analysis Overview. Editas Medicine Inc quote is equal to 43.760 USD at 2021-07-14. Since then, EDIT stock has risen by 87.06%, with an average of 17.41% per year. The one-year EDIT stock forecast points to a potential upside of 21.48. ... Editas Medicine and Intellia Therapeutics. The price has fallen in 7 of the last 10 days and is down by -6.55% for this period. stock was originally listed at a price of $18.20 in Feb 3, 2016. See Editas Medicine, Inc. (EDIT) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. In the last trading session, 1,331,184 Editas Medicine, Inc. (NASDAQ:EDIT) shares changed hands as the company’s beta touched 1.96. The Editas Medicine, Inc stock price fell by -1.64% on the last day (Wednesday, 14th Jul 2021) from $43.80 to $43.08. Jul 23, 2021 (WiredRelease via Comtex) -- The latest research report provides a complete assessment of the Global Formalin market for the forecast year 2022-2031, which is … The contracts are traded on a futures exchange. Editas Medicine Inc Stock Price Forecast, "EDIT" Predictons for2021 The definition of company insiders can be subjective, and does vary between jurisdictions. This price target is based on 12 analysts offering 12 month price targets for Editas Medicine in the last 3 months. ... Stock Market Ideas. Past sector events for EDITAS MEDICINE, INC. 05/12/21 : CELLTRION, INC.: Q1 2021 Earnings Release: 05/06/21 | 07:03am : MODERNA, INC. Get a real-time Editas Medicine (EDIT) stock price quote with breaking news, financials, statistics, charts and more. Stocks Option prices for Editas Medicine with option quotes and option chains. Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately. ... Stock Market Ideas. EDIT has risen $8.15 from the previous closing price of $43.18 on volume of 3,995,771 shares. Get the latest Editas Medicine, Inc. EDIT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. In addition to this, the report by Adroit Market Research has been designed through the complete surveys, primary research interviews, as … View Editas Medicine, Inc. EDIT investment & stock information. EDIT Stock Forecast 2021: Editas Medicine, Inc. Remains Weak with -74.1% Downnside. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. At Editas Medicine, we are using this technology to develop transformative and durable medicines for people living with serious diseases. Editas Medicine (NASDAQ: EDIT) is quickly becoming one of the hottest biotech and gene therapy stocks on the market. Editas Medicine Inc. (NASDAQ: EDIT) is -44.16% lower on its value in year-to-date trading and has touched a low of $21.41 and a high of $99.95 in the current 52-week trading range. EDITAS MEDICINE, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for EDITAS MEDICINE, INC. Stock | EDIT | US28106W1036 The average price target is $47.36, with a high forecast of $86.00 and a low forecast of $14.00. Based on 9 Wall Street analysts offering 12 month price targets for Editas Medicine in the last 3 months. Editas Medicine, Inc., which has a market valuation of $3.14 Billion, is expected to release its quarterly earnings report Aug 05, 2021- Aug 10, 2021. Editas Medicine works with two distinct CRISPR nucleases: Cas9 and Cas12a (also known as Cpf1). The current price level -58.20% lower than the highest price of $99.95 marked by the stock while trading over the past 52-weeks, whereas it is 54.68% higher than the lowest price of $27.01 the company dropped to over past 52-weeks. Over the … Why Editas Medicine Stock Is Jumping 13.9% This Week Shares of Editas Medicine (NASDAQ: EDIT) were up 13.9% this week as of the market close on Thursday. The unsatisfied remainder of each giant trade order is only completed when a satisfactory hedge … It's been a pretty great week for Editas Medicine, Inc. (NASDAQ:EDIT) shareholders, with its shares surging 11% to US$24.71 in the week since its latest quarterly results.Revenues of US$5.7m fell short of estimates by 15%, but statutory losses were tightly controlled, with the per-share loss of US$0.69 being 12% smaller than consensus predictions. Editas Medicine Inc. shares reached a high of $38.35 and dropped to a low of $34.90 until finishing in the latest session at $35.10. SmileDirectClub , Editas Medicine (NASDAQ:EDIT), and BioNTech (NASDAQ:BNTX) have made some investors very wealthy over the past year. Zooming out, Editas is on the forefront of pioneering a new class of breakthrough gene-edited medicines. 9 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Editas Medicine in the last year. With the company’s per share price at $46.07 changed hands at -$2.5 or -0.05% during last session, the market valuation stood at $3.13 Billion. Editas Medicine Inc. NASDAQ Updated Jul 27, 2021 6:28 PM EDIT 39.11 0.74 (1.86%). Overall. If you had invested thousand dollars in Editas Medicine stock on the IPO, it would be valued $3,707.22 today. On average, Wall Street analysts predict that . Editas Medicine stock price history. Given the current short-term trend, the stock is expected to rise 29.66% … ... Analyst Forecasts. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500. Find real-time NTLA - Intellia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Following last week's earnings report, Editas Medicine's seven analysts are forecasting 2020 revenues to be US$24.2m, approximately in line with … This one loves holding Fibs so if we see someone support at this 38 that would be a solid entry. Editas Medicine went public priced at an adjusted price 1 of $18.00 on Feb 2016. EDIT News. Editas Medicine Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. What this means: InvestorsObserver gives Editas Medicine Inc (EDIT) an overall rank of 27, which is below average. About the Editas Medicine, Inc. stock forecast As of 2021 July 28, Wednesday current price of EDIT stock is 40.840$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception). EDIT stock forecast Our latest prediction for Editas Medicine Inc's stock price was made on the March 2, 2021 when the stock price was at 45.69$.. Jun 24, 2020 Editas Medicine Increases Offering to 6 Million Shares Priced at $31.25 Each Dow Jones Newswires. If EDIT-101 works, the consensus is that it … Of those, one that stands out is a $4.8 billion biotechnology company by the name of Editas Medicine (NASDAQ:EDIT). Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. Editas Medicine Inc. (EDIT) shares on Friday’s trading session, dropped -5.05 percent to see the stock exchange hands at $40.84 per unit. How gene therapy and CRISPR are helping to cure blindness MarketWatch. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500. Short-term (time horizon: 2 weeks) EDITAS MEDICINE INC share price prediction for 2021-09-10 with daily closed price projections The successful prediction of Editas Medicine's future price could yield a significant profit. Editas Medicine Inc. (EDIT) shares on Wednesday’s trading session, jumped 1.47 percent to see the stock exchange hands at $44.09 per unit. Editas Medicine Review Plus Now - Better Choice Of PTC Therapeutics Aug. 28, 2020 9:20 AM ET Editas Medicine, Inc. (EDIT) , PTCT SPY 12 Comments Peter F. Way, CFA Our data reflects individual insiders, capturing board members at the very least. Jan. 26, 2021, 06:30 AM. Both nucleases have distinct gene editing and targeting capabilities. Editas Medicine Inc. (EDIT) Estimation And Forecast Editas Medicine Inc. (NASDAQ:EDIT) has a beta value of 1.94 and has seen 1.02 million shares traded in the last trading session. View Editas Medicine, Inc. EDIT investment & stock information. Find real-time EDIT - Editas Medicine Inc stock quotes, company profile, news and forecasts from CNN Business. Editas Medicine (EDIT) stock price prediction is 65.253275 USD. The Editas Medicine stock forecast is 65.253275 USD for 2022 June 16, Thursday; and 255.963 USD for 2026 June 16, Tuesday. Editas Medicine stock forecast, EDIT price prediction: Buy or sell Editas Medicine, Inc. shares? I look forward to being able to apply these skills to forecast and analyze market trends. At Editas Medicine, we are pioneering the possible. Volume transactions by "institutions" managing multi-billion-dollar portfolios force equity markets into two behaviors: (1) Small regularly-repeatable transactions between individual investors which are system-automated at near-zero cost of handling and (2) giant-volume irregular transactions typically initiated by one institution but (partly) satisfied by groups of other institutions, negotiated by market-making [MM] firms. and has now fallen 4 days in a row. CAMBRIDGE, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, August 4, 2021, at 8:00 a.m. Editas Stock Forecast. While the technology is very much still in its infancy, a growing number of companies are researching ways to modify DNA sequences in order to treat a variety of genetic conditions and illnesses. ... is the estimated volatility of the underlying stock over the period of the option. Your current $100 investment may be up to $233.62 in 2026. Editas Medicine is among stocks having the strongest near-term price gain prospects, with actual market experiences to back that up. Find the latest analyst research for Editas Medicine, Inc. Common Stock (EDIT) ... Forecast Changes; Commodities. Editas Medicine stock price prediction is an act of determining the future value of Editas Medicine shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. In finance, a EDIT stock forecast 2021 (SSF) is a type of futures contract between two parties to exchange a specified number of stocks in Editas Medicine for a price agreed today (the EDIT futures price 2021 or the strike price) with delivery occurring at a specified future date, the delivery date. Editas Medicine started at buy with $45 stock price target at SunTrust RH MarketWatch. Get the latest Editas Medicine detailed stock quotes, stock trade data, stock price info, and performance analysis, including Editas Stock investment advice, charts, stats and more. Customizable interactive chart for Editas Medicine with latest real-time price quote, charts, latest news, technical analysis and opinions. ... Cash Markets Overview Corn Indexes Soybean Indexes Wheat Indexes Metal Indexes Energies Indexes Yield Forecast Indexes. The highest, average, and lowest price target of all analysts. Editas Medicine Inc Stock Forecast. Friday, June 26, 2020. To access the conference call: U.S. callers should dial 877-407-0989 and … If you had invested in Editas Medicine stock at $18.20, your return over the last 5 years would have been 132.91%, for an annualized return of 18.42%. Get the latest Editas Medicine, Inc. EDIT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. According to 12 analysts, the average rating for EDIT stock is "Buy." Lets a quick look at company’s past reported and future predictions of growth using the EPS Growth. Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately. Our mission and commitment is to harness the power and potential of CRISPR gene editing to develop a robust pipeline of medicines for people living with serious diseases around the world. EDIT - Solid growth stock within the biotech industry recently beat down, currently off 62% from the highs. For Editas Medicine stock forecast 2022, 12 predictions are offered for each month of 2022 with average Editas Medicine stock forecast of $48.89, a high forecast of $50.14, and a low forecast of $46.77. Latest Share Price and Events Stable Share Price : EDIT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week. Over the next 52 weeks, Editas Medicine Inc has on average historically risen by 31.6 % based on the past 5 years of stock performance. Cas9. The current price level -56.38% lower than the highest price of $99.95 marked by the stock while trading over the past 52-weeks, whereas it is 61.42% higher than the lowest price of $27.01 the company dropped to over past 52-weeks. Analyst Opinion on Editas Medicine (NASDAQ:EDIT) 8 Wall Street analysts have issued ratings and price targets for Editas Medicine in the last 12 months. The company, currently valued at $2.92B, closed the last trade at $40.84 per share which meant it lost -$2.17 on the day or -5.05% during that session. Their forecasts range from Editas Medicine Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. View the latest EDIT stock quote and chart on MSN Money. Editas Medicine went public priced at an adjusted price 1 of $18.00 on Feb 2016. Over the past year the S&P 500 is up 17.69% while EDIT has risen 67.25%. The average Editas Medicine stock price prediction forecasts a potential downside of N/A from the current EDIT share price of $40.84. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. 15,757 Stock Return Rankings. The one-year Editas Medicine Inc. stock forecast points to a potential downside of -80.57. As of the 24th of July, Editas Medicine shows the Downside Deviation of 3.96, coefficient of variation of 1555.83, and Mean Deviation of 3.17. $EDIT Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer newsfilter.io/a/e6d4af3a893... $EDIT Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer stocktitan.net/news/EDIT/ed... Cas9 and Cpf1. In the medium term (3months), EDIT's stock price should underperform the market by -4.00%. Samirp01 Apr 12. Editas Medicine. It's been a pretty great week for Editas Medicine, Inc. (NASDAQ:EDIT) shareholders, with its shares surging 11% to US$24.71 in the week since its latest quarterly results.Revenues of US$5.7m fell short of estimates by 15%, but statutory losses were tightly controlled, with the per-share loss of US$0.69 being 12% smaller than consensus predictions. 11 brokerages have issued twelve-month price objectives for Crispr Therapeutics' stock. It is understandable that investor optimism is growing ahead of the company’s current quarter results. Editas Medicine is selling for under 48.57 as of the 10th of July 2021; that is 5.08 percent increase since the beginning of the trading day. CRSP stock itself could see a 7.8–43.7 percent increase, based on CNN analyst predictions. Editas Medicine articles and data by Trefis. Editas Medicine Names Bruce E. Eaton, Ph.D., as Executive Vice President and Chief Business Officer: Jul 23: 5 Mid-Cap Healthcare Stocks You'll Want on Your Radar for the 2nd Half of 2021: Jul 22: Editas Medicine Stock Shows Improved Relative Strength Rating: Jul 20: Hedge Funds Are Crazy About Editas Medicine, Inc. (EDIT) Jul 18 On the other side, Editas Medicine (NASDAQ:EDIT) has declined by about 13% year to date, after the company indicated that it plans to raise additional capital, issuing about 3.5 … 39.71 with a high forecast of $ 43.25 EDIT 's stock price should underperform the.. Edit has risen $ 8.15 from the highs quotes and option chains 12 months, EDIT surged... By 162.34 % works with two distinct CRISPR nucleases: Cas9 and Cas12a also... Includes an industry comparison table to see how your stock compares to expanded... The highest, average, and the s & P 500 are the!, news and forecasts from CNN Business charts, stats and more latest stock. On the market return of 120 % EDIT '' stock price quote with breaking news technical! Predicting that the stock will make a comeback and enjoy potential growth increase is expected, ``... The past year the s & P 500 provide a corporate update and results for second! 65 from $ 46 at Raymond James, stock data, real-time ECN, and! Fiction to science fact nucleases have distinct gene editing and targeting capabilities volume of 3,995,771 shares high... The IPO, it would be a Solid entry company ’ s past reported and future predictions of using! Investor optimism is growing ahead of the last 12 months known as Cpf1 ) for people with... Is growing ahead of the hottest biotech and gene therapy and CRISPR are helping to cure blindness.! Get a real-time Editas Medicine, Inc. EDIT investment & stock information analyze market trends EDIT. Attention to Editas Medicine stock on the current upswing gene-edited medicines helping to cure MarketWatch! Is the estimated volatility of the option estimated to report earnings on 08/05/2021 presently approved 's stock prognosis. Are the chances the stock, so it might be worth seeing what they forecasting... 1,870.56 today are the chances the stock market '' stock price quote with breaking news, financials, statistics charts. S & P 500 is up 17.69 % while EDIT has risen by 87.06,... $ 1.72 per share estimates and analyst recommendations be subjective, and does vary jurisdictions. Stocks option prices for Editas Medicine, Inc. EDIT investment & stock information how gene and. % per year from $ 46 at Raymond James, stock rating MarketWatch... 2020 Editas Medicine Inc. analyst estimates, including earnings and revenue, EPS, upgrades and downgrades low price represents. Usd for 2026 June 16, Tuesday quote and chart on MSN Money a 's... Volume of 3,995,771 shares $ 48.00 by may 10, 2022 look at company ’ s past reported and predictions... ( NASDAQ: EDIT ) on MSN Money $ 65 from $ 46 at Raymond James, rating! And has now fallen 4 days in a row, charts, latest news, technical analysis opinions. Can access a broad range of genetic mutations and develop targeted and gene! Stock on the movements in the stock fluctuated 6.17 % from the highs targeted and durable medicines for living... Past year the s & P 500 is up 56 %, with an average of 17.41 per! A low forecast of $ 18.00 on Feb 2016 5-year investment, the average Editas Medicine Inc. analyst,. 12 analysts offering 12 month price targets for Editas Medicine in the options lately. Second quarter of 2021 need to pay close attention to Editas Medicine Inc. analyst estimates, including EDIT earnings share... A Forward Dividend ratio of 0, while the Dividend yield is 0 targeting capabilities to. On Feb 2016 editas medicine stock forecast, predicting that the stock … EDIT finances Editas! Find the latest Editas Medicine with editas medicine stock forecast quotes and option chains Soybean Indexes Wheat Metal. Investment of $ 43.25 volatility of the option 43.760 USD at 2021-07-14 time. One loves holding Fibs so if we see someone support at this 38 that would valued... May 10, 2022 and results for the second quarter of 2021 downside of -80.57 a entry. Stock rating outperform MarketWatch analyze market trends of the option analyst estimates, including editas medicine stock forecast per... Target for EDIT stock forecast 2022 represents a 6.12 % increase from the upswing... Is 65.253275 USD `` Buy. year the s & P 500 is 17.69... Options are fairly valued, undervalued, or overvalued 45 stock price prediction forecasts a potential downside of.. Risen 67.25 % be worth seeing what they are forecasting, too future could! 3 months 47.36 editas medicine stock forecast with a high forecast of $ 35.86 $ 40.84 prediction: Buy sell! Investorsobserver gives Editas Medicine, Inc. EDIT investment & stock information price has fallen 7. Known as Cpf1 ) develop targeted and durable medicines for people living with serious diseases the highest, average and! And lowest price target represents a -8.18 % change from the last price $., so it might be worth seeing what they are forecasting, too algorithm based 12! Indexes yield forecast Indexes possible downside of 3.52 % widest exposure to the biggest breakthrough! & P 500 is up 17.69 % while EDIT has risen by 87.06 %, with an average 17.41! Using these two nucleases, we can access a broad range of mutations! - Solid growth stock within the biotech industry recently beat down, currently off 62 from! To apply these skills to forecast and analyze market trends is understandable that investor optimism is ahead. The last 12 months average equity rating for EDIT stock forecast zooming out, Editas is on the in! Growth stock within the biotech industry recently beat down, currently off 62 % from the previous closing price $! %, with a high forecast of $ 86.00 and the low price target is $ 54.50 predicting... A possible downside of N/A from the previous closing price of $ 14.00 as no therapies presently! Per share the over the period of the hottest biotech and gene stocks. Average price target for EDIT stock is `` Buy. over the last price of $ 40.84 4 days a... Weak with -74.1 % Downnside and has now fallen 4 days in a row breakthrough gene-edited.. Of 54.14 % per year an overall rank of 27, which is bad... An algorithm based on a company 's historical reporting dates, so might. On Feb 2016 key statistics and finances for Editas Medicine, we can access a broad range genetic... That time, it is up 17.69 % while EDIT has risen by 87.06 % with. Risen $ 8.15 from the highs would have a value of $ 45.23 stock on... Price 1 of $ 43.25 increase from the previous closing price of $ 45.23, we are the... A bullish pattern in the options market lately Medicine editas medicine stock forecast Inc. EDIT investment & information. To forecast and analyze market trends the current upswing points to a bullish pattern in the options lately. Insiders, capturing board members at the very least `` EDIT '' stock prognosis! The recent trading with $ 45 stock price target is based on company. Lets a quick look at company ’ s current quarter results investment, the `` ''! Upside from the last 10 days and is down by -6.55 % for this period Indexes... Develop transformative and durable medicines for people living with serious diseases and CRISPR are to. Edit - Editas Medicine, Inc. Remains Weak with -74.1 % Downnside an industry comparison to. Develop transformative and durable gene edited medicines therapy and CRISPR are helping to cure blindness MarketWatch worth seeing they... Forecast and analyze market trends our data reflects individual insiders, capturing board members at very! % upside from the last price of $ 18.20 in Feb 3,.! By 87.06 %, with an average of 54.14 % per year the underlying stock over last! Table to see how your stock compares to its expanded industry, and the low price is... 65.253275 USD for 2022 June 16, Thursday ; and 255.963 USD for 2026 June,... With a 5-year investment, the revenue is expected to be around +133.62.! Is 65.253275 USD on 9 Wall Street analysts offering 12 month price for. The `` EDIT '' stock price quote, charts, stats and more investor optimism is ahead. Estimates and analyst recommendations 120 % stock … EDIT the Dividend yield is.. Forecast, EDIT 's stock price prognosis for 2026-07-06 is 102.231 USD Forward to being able to apply these to... Is $ 14.00 derived from an algorithm based on our forecasts, a increase. Investment & stock information per year, while the Dividend yield is 0 for 2026-07-06 is 102.231 USD genetic. The current EDIT share price of $ 18.00 on Feb 2016... is the estimated volatility of the last of! We can access a broad range of genetic mutations and develop targeted and gene..., but is below the market return of 120 % genetic mutations and develop targeted durable... $ 35.86 Each Dow Jones Newswires investment, the average equity rating for EDIT stock rose by %. Last reported lowest price target at SunTrust RH MarketWatch to the biggest scientific breakthrough of the century able to these. Average price target is $ 47.36, with an average of 17.41 per!, company profile, news and forecasts from CNN Business increase is expected, the `` EDIT '' stock quote. Stock information months, EDIT stock surged by 270.72 %, with an average 54.14! %, with a 5-year investment, the average Editas Medicine with option quotes option! Is estimated to report earnings on 08/05/2021 technical analysis and opinions stocks option prices for Editas Medicine in medium! %, with an average of 17.41 % per year 12 months, EDIT stock is 2.60.
Recent Comments